Current Infectious Disease Reports

, Volume 14, Issue 1, pp 102–109 | Cite as

Key Concepts in the Early Immunology of HIV-1 Infection

  • Basile Siewe
  • Alan Landay
HIV/AIDS (RD MacArthur, Section Editor)


Though HIV-1 is a sexually transmitted infection, the gut associated lymphoid tissue (GALT) that houses about 60% of the body’s total immune cells is unequivocally the earliest and most important target of HIV-1. In this review we summarize recent data regarding the early events in HIV-1 pathogenesis, with special emphasis on pathogenic effects on the GALT.


HIV-1 SIV AIDS GALT T cells B cells Natural killer cells Dendritic cells Early/acute infection Chronic infection Immune activation Microbial translocation Peak viremia Viral set-point Antibodies Innate immune system Adaptive immune system African green monkeys Rhesus macaques 


Papers of particular interest recently published, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Pantaleo G, Graziosi C, Fauci AS. New concepts in the immunopathogenesis of human immunodeficiency virus infection. N Engl J Med. 1993;328:327–35.PubMedCrossRefGoogle Scholar
  2. 2.
    McMichael AJ, Borrow P, Tomaras GD, et al.: The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 10:11–23.Google Scholar
  3. 3.
    Highleyman L. Detuned assay used to track recent infections. Beta. 1999;12(6):78.Google Scholar
  4. 4.
    Centlivre M, Sala M, Wain-Hobson S, Berkhout B. In HIV-1 pathogenesis the die is cast during primary infection. Aids. 2007;21:1–11.PubMedCrossRefGoogle Scholar
  5. 5.
    Brenchley JM, Schacker TW, Ruff LE, et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med. 2004;200:749–59.PubMedCrossRefGoogle Scholar
  6. 6.
    Veazey RS, DeMaria M, Chalifoux LV, et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science. 1998;280:427–31.PubMedCrossRefGoogle Scholar
  7. 7.
    Johnston MI, Fauci AS. An HIV vaccine–evolving concepts. N Engl J Med. 2007;356:2073–81.PubMedCrossRefGoogle Scholar
  8. 8.
    Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol. 2004;2:33–42.PubMedCrossRefGoogle Scholar
  9. 9.
    Haaland RE, Hawkins PA, Salazar-Gonzalez J, et al. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog. 2009;5:e1000274.PubMedCrossRefGoogle Scholar
  10. 10.
    Miller CJ, Li Q, Abel K, et al. Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol. 2005;79:9217–27.PubMedCrossRefGoogle Scholar
  11. 11.
    Salazar-Gonzalez JF, Salazar MG, Keele BF, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med. 2009;206:1273–89.PubMedCrossRefGoogle Scholar
  12. 12.
    Douek DC, Picker LJ, Koup RA. T cell dynamics in HIV-1 infection. Annu Rev Immunol. 2003;21:265–304.PubMedCrossRefGoogle Scholar
  13. 13.
    Li Q, Duan L, Estes JD, et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature. 2005;434:1148–52.PubMedGoogle Scholar
  14. 14.
    Arthos J, Cicala C, Martinelli E, et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol. 2008;9:301–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Zhang ZQ, Wietgrefe SW, Li Q, et al. Roles of substrate availability and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection. Proc Natl Acad Sci U S A. 2004;101:5640–5.PubMedCrossRefGoogle Scholar
  16. 16.
    • Cicala C, Martinelli E, McNally JP, et al.: The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc. Natl. Acad. Sci. U S A 2009, 106:20877–82. The authors identify a T cell subset close to transmission sites that is very susceptible to infection and expresses the gut homing receptor alpha4beta7. Migration of these infected cells to the gut, might be a crucial link between infection site and the GALT. PubMedCrossRefGoogle Scholar
  17. 17.
    Altfeld M, Fadda L, Frleta D, Bhardwaj N: DCs and NK cells: critical effectors in the immune response to HIV-1. Nat. Rev. Immunol. 11:176–86.Google Scholar
  18. 18.
    Gringhuis SI, van der Vlist M, van den Berg LM, et al.: HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat Immunol 11:419–26.Google Scholar
  19. 19.
    Geijtenbeek TB, Kwon DS, Torensma R, et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell. 2000;100:587–97.PubMedCrossRefGoogle Scholar
  20. 20.
    Moir S, Malaspina A, Li Y, et al. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. J Exp Med. 2000;192:637–46.PubMedCrossRefGoogle Scholar
  21. 21.
    Borrow P, Lewicki H, Hahn BH, et al. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol. 1994;68:6103–10.PubMedGoogle Scholar
  22. 22.
    Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol. 1994;68:4650–5.PubMedGoogle Scholar
  23. 23.
    Mattapallil JJ, Douek DC, Hill B, et al. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature. 2005;434:1093–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Mowat AM, Viney JL. The anatomical basis of intestinal immunity. Immunol Rev. 1997;156:145–66.PubMedCrossRefGoogle Scholar
  25. 25.
    Boirivant M, Viora M, Giordani L, et al. HIV-1 gp120 accelerates Fas-mediated activation-induced human lamina propria T cell apoptosis. J Clin Immunol. 1998;18:39–47.PubMedCrossRefGoogle Scholar
  26. 26.
    Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science. 1999;283:857–60.PubMedCrossRefGoogle Scholar
  27. 27.
    Phillips AN. Reduction of HIV concentration during acute infection: independence from a specific immune response. Science. 1996;271:497–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Hansen SG, Ford JC, Lewis MS, et al.: Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473:523–7.Google Scholar
  29. 29.
    Zhang ZQ, Casimiro DR, Schleif WA, et al. Early depletion of proliferating B cells of germinal center in rapidly progressive simian immunodeficiency virus infection. Virology. 2007;361:455–64.PubMedCrossRefGoogle Scholar
  30. 30.
    •• Levesque MC, Moody MA, Hwang KK, et al.: Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med 2009, 6:e1000107. The authors demonstrate B cell polyclonal activation, follicular damage and germinal center loss in the gut during early infection, providing insight into the high rate of decline in the HIV-1 antibody response and delay in anti-HIV-1 antibody reponses. PubMedCrossRefGoogle Scholar
  31. 31.
    Das A, Veazey RS, Wang X, et al.: Simian immunodeficiency virus infection in rhesus macaques induces selective tissue specific B cell defects in double positive CD21+CD27+ memory B cells. Clin Immunol. A GALT B cell subset is identified that is specifically targeted during HIV-1 infection and might be important in disease progression. Google Scholar
  32. 32.
    Das A, Xu H, Wang X, et al.: Double-positive CD21+CD27+ B cells are highly proliferating memory cells and their distribution differs in mucosal and peripheral tissues. PLoS One 6:e16524.Google Scholar
  33. 33.
    Titanji K, Velu V, Chennareddi L, et al.: Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques. J. Clin. Invest. 120:3878–90. The authors identify a pathway with potential therapeutic mediating loss of memory B cells during early infection. Google Scholar
  34. 34.
    Dandekar S, George MD, Baumler AJ: Th17 cells, HIV and the gut mucosal barrier. Curr Opin HIV AIDS 5:173–8.Google Scholar
  35. 35.
    Conti HR, Shen F, Nayyar N, et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J Exp Med. 2009;206:299–311.PubMedCrossRefGoogle Scholar
  36. 36.
    Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485–517.PubMedCrossRefGoogle Scholar
  37. 37.
    Dubin PJ, Kolls JK. Th17 cytokines and mucosal immunity. Immunol Rev. 2008;226:160–71.PubMedCrossRefGoogle Scholar
  38. 38.
    Favre D, Lederer S, Kanwar B, et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog. 2009;5:e1000295.PubMedCrossRefGoogle Scholar
  39. 39.
    Knoechel B, Lohr J, Kahn E, et al. Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen. J Exp Med. 2005;202:1375–86.PubMedCrossRefGoogle Scholar
  40. 40.
    Silvestri G, Sodora DL, Koup RA, et al. Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity. 2003;18:441–52.PubMedCrossRefGoogle Scholar
  41. 41.
    Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179:859–70.PubMedCrossRefGoogle Scholar
  42. 42.
    Liu Z, Cumberland WG, Hultin LE, et al. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the Multicenter AIDS Cohort Study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16:83–92.PubMedCrossRefGoogle Scholar
  43. 43.
    Liu Z, Hultin LE, Cumberland WG, et al. Elevated relative fluorescence intensity of CD38 antigen expression on CD8+ T cells is a marker of poor prognosis in HIV infection: results of 6 years of follow-up. Cytometry. 1996;26:1–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Deeks SG, Kitchen CM, Liu L, et al. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood. 2004;104:942–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Nilsson J, Kinloch-de-Loes S, Granath A, et al. Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV infection. Aids. 2007;21:565–74.PubMedCrossRefGoogle Scholar
  46. 46.
    Sodora DL, Silvestri G. Immune activation and AIDS pathogenesis. Aids. 2008;22:439–46.PubMedCrossRefGoogle Scholar
  47. 47.
    Brenchley JM, Price DA, Douek DC. HIV disease: fallout from a mucosal catastrophe? Nat Immunol. 2006;7:235–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365–71.PubMedCrossRefGoogle Scholar
  49. 49.
    •• Baenziger S, Heikenwalder M, Johansen P, et al.: Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. Blood 2009, 113:377–88. A well-designed study clearly establishing the contribution of TLR stimulation to immune activation. PubMedCrossRefGoogle Scholar
  50. 50.
    Mandl JN, Barry AP, Vanderford TH, et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med. 2008;14:1077–87.PubMedCrossRefGoogle Scholar
  51. 51.
    Stacey AR, Norris PJ, Qin L, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol. 2009;83:3719–33.PubMedCrossRefGoogle Scholar
  52. 52.
    Diop OM, Ploquin MJ, Mortara L, et al. Plasmacytoid dendritic cell dynamics and alpha interferon production during Simian immunodeficiency virus infection with a nonpathogenic outcome. J Virol. 2008;82:5145–52.PubMedCrossRefGoogle Scholar
  53. 53.
    Malleret B, Maneglier B, Karlsson I, et al. Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression. Blood. 2008;112:4598–608.PubMedCrossRefGoogle Scholar
  54. 54.
    Mace K, Duc Dodon M, Gazzolo L. Restriction of HIV-1 replication in promonocytic cells: a role for IFN-alpha. Virology. 1989;168:399–405.PubMedCrossRefGoogle Scholar
  55. 55.
    Lapenta C, Santini SM, Proietti E, et al. Type I interferon is a powerful inhibitor of in vivo HIV-1 infection and preserves human CD4(+) T cells from virus-induced depletion in SCID mice transplanted with human cells. Virology. 1999;263:78–88.PubMedCrossRefGoogle Scholar
  56. 56.
    Adalid-Peralta L, Grangeot-Keros L, Rudent A, et al. Impact of highly active antiretroviral therapy on the maturation of anti-HIV-1 antibodies during primary HIV-1 infection. HIV Med. 2006;7:514–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Sabado RL, O’Brien M, Subedi A, et al.: Evidence of dysregulation of dendritic cells in primary HIV infection. Blood 116:3839–52.Google Scholar
  58. 58.
    Jacquelin B, Mayau V, Targat B, et al. Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest. 2009;119:3544–55.PubMedGoogle Scholar
  59. 59.
    Biron CA, Nguyen KB, Pien GC, et al. Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol. 1999;17:189–220.PubMedCrossRefGoogle Scholar
  60. 60.
    Alter G, Teigen N, Ahern R, et al. Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J Infect Dis. 2007;195:1452–60.PubMedCrossRefGoogle Scholar
  61. 61.
    Mavilio D, Benjamin J, Daucher M, et al. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci U S A. 2003;100:15011–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Mavilio D, Lombardo G, Benjamin J, et al. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci U S A. 2005;102:2886–91.PubMedCrossRefGoogle Scholar
  63. 63.
    Rinaldo CR. Dendritic cell-based human immunodeficiency virus vaccine. J Intern Med. 2009;265:138–58.PubMedCrossRefGoogle Scholar
  64. 64.
    •• Goonetilleke N, Liu MK, Salazar-Gonzalez JF, et al.: The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med 2009, 206:1253–72. This paper clearly demonstrates the crucial importance of the anti-HIV-1 mediated CD8 response in curbing viral replication during acute infection, with potential implications for vaccine development. PubMedCrossRefGoogle Scholar
  65. 65.
    Keele BF, Giorgi EE, Salazar-Gonzalez JF, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A. 2008;105:7552–7.PubMedCrossRefGoogle Scholar
  66. 66.
    Rosenberg ES, Billingsley JM, Caliendo AM, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science. 1997;278:1447–50.PubMedCrossRefGoogle Scholar
  67. 67.
    Oxenius A, Fidler S, Brady M, et al. Variable fate of virus-specific CD4(+) T cells during primary HIV-1 infection. Eur J Immunol. 2001;31:3782–8.PubMedCrossRefGoogle Scholar
  68. 68.
    Tomaras GD, Yates NL, Liu P, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol. 2008;82:12449–63.PubMedCrossRefGoogle Scholar
  69. 69.
    Wei X, Decker JM, Wang S, et al. Antibody neutralization and escape by HIV-1. Nature. 2003;422:307–12.PubMedCrossRefGoogle Scholar
  70. 70.
    Chun TW, Engel D, Berrey MM, et al. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection. Proc Natl Acad Sci U S A. 1998;95:8869–73.PubMedCrossRefGoogle Scholar
  71. 71.
    Peruchon S, Chaoul N, Burelout C, et al. Tissue-specific B-cell dysfunction and generalized memory B-cell loss during acute SIV infection. PLoS One. 2009;4:e5966.PubMedCrossRefGoogle Scholar
  72. 72.
    •• Moir S, Buckner CM, Ho J, et al.: B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood 116:5571–9. A seminal work on the dysregulation of the B cell compartment from the earliest stages of infection to post initiation of ART therapy. Google Scholar
  73. 73.
    Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000;6:207–10.PubMedCrossRefGoogle Scholar
  74. 74.
    Watkins JD, Siddappa NB, Lakhashe SK, et al.: An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV. PLoS One 6:e18207.Google Scholar
  75. 75.
    Hessell AJ, Poignard P, Hunter M, et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med. 2009;15:951–4.PubMedCrossRefGoogle Scholar
  76. 76.
    Hessell AJ, Rakasz EG, Poignard P, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009;5:e1000433.PubMedCrossRefGoogle Scholar
  77. 77.
    •• Rasmussen RA, Lakhashe SK, Ruprecht RM: Bimodal AIDS vaccine approach: induction of cellular as well as humoral immunity can protect from systemic infection. Vaccine 28 Suppl 2:B25–31. This study demonstrates that an efficacious vaccine might require a combination of cellular and humoral immune components. Google Scholar
  78. 78.
    Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209–20.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.ChicagoUSA
  2. 2.ChicagoUSA

Personalised recommendations